Cullinan is building a broader T-cell engager pipeline in autoimmune disease and cancer, while partnered zipalertinib remains its most advanced oncology commercialization opportunity; the company’s pipeline currently lists the relapsed-NSCLC application with a February 27, 2027 PDUFA date.
The regulatory path has moved from clinical success toward formal review. Cullinan has begun the first-line NDA submission process for zipalertinib plus chemotherapy under FDA’s Real-Time Oncology Review program, with the complete submission expected by year-end 2026. 〔0〕 RTOR can let FDA begin reviewing key efficacy and safety data earlier, but it does not guarantee approval or change the normal statutory approval standard.
The underlying trial result is supportive, but the filing adds process rather than new clinical proof. The Phase 3 REZILIENT3 trial had already met its primary endpoint, and those results were presented at the 2026 World Conference on Lung Cancer. 〔1〕 The market already knew the study had succeeded; today’s incremental news is that FDA agreed to the RTOR submission route and Cullinan has started the filing process.
| Approval opportunity | Potential Taiho milestone |
|---|---|
| Second-line U.S. approval | $30 million (Item 8.01) |
| First-line U.S. approval | Up to $100 million (Item 8.01) |
Two regulatory catalysts now sit on the timeline. The monotherapy application for previously treated patients remains under FDA review with a February 27, 2027 PDUFA target date, while the first-line combination application is expected to be completed by year-end 2026. 〔2〕
Bottom line: This advances zipalertinib from strong Phase 3 data into the regulatory queue and modestly improves execution visibility. It matters because first-line approval would expand the drug’s opportunity and unlock a potential $100 million milestone, but the filing is a submission update—not an approval or a new clinical readout.
Read the original 8-K on SEC EDGAR ↗